We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth

In This Article:

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Given this risk, we thought we'd take a look at whether C4 Therapeutics (NASDAQ:CCCC) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for C4 Therapeutics

When Might C4 Therapeutics Run Out Of Money?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In March 2024, C4 Therapeutics had US$258m in cash, and was debt-free. Importantly, its cash burn was US$93m over the trailing twelve months. That means it had a cash runway of about 2.8 years as of March 2024. That's decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
NasdaqGS:CCCC Debt to Equity History May 22nd 2024

How Well Is C4 Therapeutics Growing?

We reckon the fact that C4 Therapeutics managed to shrink its cash burn by 21% over the last year is rather encouraging. Unfortunately, however, operating revenue declined by 26% during the period. Considering both these factors, we're not particularly excited by its growth profile. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Easily Can C4 Therapeutics Raise Cash?

C4 Therapeutics seems to be in a fairly good position, in terms of cash burn, but we still think it's worthwhile considering how easily it could raise more money if it wanted to. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.